Here are three insights:
1. The company’s shares closed at $49.23 with Zacks issuing a “buy” ranking.
2. With a market cap. of $920 million, Mazor has an anticipated long-term earnings per share growth of 7.9 percent.
3. The company is outperforming the industry, with its shares moving 121.5 percent in the past year, compared to the industry’s 6.3 percent increase.
More articles on devices:
Medtronic to study Infuse in PLF, TLIF spine surgeries in new pilot trials: 5 things to know
Medtronic, NuVasive, InVivo Therapeutics & more: 6 device company notes
Stryker completes Novadaq Technologies acquisition: 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
